A compound of the general formula (I) for use in the treatment of diseases associated with a PGD2 receptor:wherein the ring A is an aromatic carbocyclic ring etc.； the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.； the ring C is an aromatic carbocyclic ring etc.； R1 is hydroxyalkyl etc.； R2 is independently a halogen atom etc.； R3 is a hydrogen atom etc.； R4 is independently a halogen atom etc.； R5 is independently a halogen atom etc.； M is carbonyl etc.； Y is a single bond etc.； L1, L2 and L3 are independently a single bond etc.； R6 and R7 are independently a hydrogen atom etc.； k is 0, 1, 2, 3 or 4； n is 0, 1 or 2； and q is 0, 1, 2 or 3； provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) R1 is not carboxy when the ring C is a benzene ring, -L3- is - (O-alkylene)-, and the substituting position of L3 and Y is an ortho-position each other in the ring C, and d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring；a pharmaceutically acceptable salt or solvate thereof.
